The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Sertindole Versus Haloperidol for Schizophrenia

Published Online:https://doi.org/10.1176/ajp.155.9.1303

To the Editor: Dan L. Zimbroff, M.D., and colleagues (1) presented interesting results of a comparative study of sertindole and haloperidol. Even though their results look promising, their study has some major limitations that the authors failed to discuss. The most important and puzzling is the high dropout rate of 51% in a relatively short (8 weeks’) study. There is also no explanation why 79 patients (16% of the whole study population) dropped out. Finally, it is not clear how many subjects were used to calculate the mean final scores in each group and why the numbers of patients in tables 2 and 3 are different.

References

1. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, and the Sertindole Study Group: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154:782–791 LinkGoogle Scholar